Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof

US11999789B2 · kind B2 · utility

Assignees

• PROMETHEUS BIOSCIENCES, INC. · US
• Cedars Sinai Medical Center · US

Inventors

• Jeffry D. Watkins · Encinitas, US
• Cindy T. Dickerson · Encinitas, US
• Rafael Rojas · San Marcos, US
• Matthew Reissman · San Diego, US
• Patricia McNeeley · San Diego, US
• Janine Bilsborough · Simi Valley, US
• Bradley Henkle · West Hollywood, US
• Stephan R. Targan · Santa Monica, US

Key dates

• Filing date: Feb 28, 2022
• Grant date: Jun 4, 2024
• Expiry date: Feb 28, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).